These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9443472)

  • 1. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography.
    Rinne JO; Sahlberg N; Ruottinen H; Någren K; Lehikoinen P
    Neurology; 1998 Jan; 50(1):152-6. PubMed ID: 9443472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different pattern of reduction of striatal dopamine reuptake sites in Alzheimer's disease and ageing.
    Kemppainen N; Marjamäki P; Röyttä M; Rinne JO
    J Neural Transm (Vienna); 2001; 108(7):827-36. PubMed ID: 11515748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.
    Rinne JO; Bergman J; Ruottinen H; Haaparanta M; Eronen E; Oikonen V; Sonninen P; Solin O
    Synapse; 1999 Feb; 31(2):119-24. PubMed ID: 10024008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia.
    Rinne JO; Laine M; Kaasinen V; Norvasuo-Heilä MK; Någren K; Helenius H
    Neurology; 2002 May; 58(10):1489-93. PubMed ID: 12034784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
    Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
    Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
    Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
    J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unchanged striatal dopamine transporter availability in narcolepsy: a PET study with [11C]-CFT.
    Rinne JO; Hublin C; Någren K; Helenius H; Partinen M
    Acta Neurol Scand; 2004 Jan; 109(1):52-5. PubMed ID: 14653850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Ruottinen H; Ruotsalainen U; Rinne UK
    Synapse; 1995 Oct; 21(2):97-103. PubMed ID: 8584980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cocaine congeners as PET imaging probes for dopamine terminals.
    Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
    J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.
    Wüllner U; Pakzaban P; Brownell AL; Hantraye P; Burns L; Shoup T; Elmaleh D; Petto AJ; Spealman RD; Brownell GL
    Exp Neurol; 1994 Apr; 126(2):305-9. PubMed ID: 7925829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.
    Kemppainen N; Ruottinen H; Nâgren K; Rinne JO
    Neurology; 2000 Jul; 55(2):205-9. PubMed ID: 10908891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
    Kaufman MJ; Madras BK
    Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
    Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
    Laihinen AO; Rinne JO; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Ruottinen HM; Rinne UK
    J Nucl Med; 1995 Jul; 36(7):1263-7. PubMed ID: 7790953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.